<DOC>
	<DOCNO>NCT00003454</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study effectiveness antineoplaston therapy treat woman stage IV breast cancer respond previous therapy .</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety possible effectiveness antineoplastons A10 AS2-1 woman stage IV breast carcinoma . - Describe response , tolerance , side effect regimen patient . OUTLINE : Patients receive gradually escalate dos antineoplaston A10 antineoplaston AS2-1 intravenous injection 6 time daily maximum tolerate dose reach . Treatment continue least 3 month absence unacceptable toxicity disease progression . Patients achieve complete response ( CR ) continue treatment additional 8 month reach CR . Tumors measure least every 2 month 1 year every 3 month 1 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV breast cancer unlikely respond exist therapy curative therapy exist Must fail prior standard therapy Measurable disease MRI CT scan Tumor must least 2 cm lymph node head , neck , axillary , inguinal , femoral area least 0.5 cm location Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal Status : Not specify Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL SGOT/SGPT great 5 time upper limit normal No hepatic failure Renal : Creatinine great 2.5 mg/dL No history renal condition contraindicate high dosage sodium Cardiovascular : No chronic heart failure No uncontrolled hypertension No history congestive heart failure No history cardiovascular condition contraindicate high dosage sodium Pulmonary : No severe lung disease , chronic obstructive pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception 4 week study participation No serious medical psychiatric disorder No active infection No serious concurrent disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy , except patient disease progression initial therapy Recovery prior immunotherapy No concurrent immunomodulating agent Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) , except patient disease progression initial therapy Recovery prior chemotherapy No concurrent antineoplastic agent Endocrine therapy : At least 12 week since prior hormonal therapy , except patient disease progression initial therapy Concurrent corticosteroid allow Recovery prior hormonal therapy Radiotherapy : At least 8 week since prior radiotherapy recover ( patient multiple tumor receive radiotherapy , , tumor may admit earlier 8 week ) Surgery : Recovered prior surgery Other : No prior antineoplaston therapy Prior cytodifferentiating agent allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>